Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLK NASDAQ:BPMC NASDAQ:GLPG NASDAQ:IONS NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLKAllakos$0.33$0.33$0.22▼$1.56$29.74M0.151.25 million shsN/ABPMCBlueprint Medicines$129.46$128.90$73.04▼$129.65$8.36B0.891.55 million shsN/AGLPGGalapagos$32.02+0.4%$31.95$22.36▼$33.86N/A0.22313,870 shs50,090 shsIONSIonis Pharmaceuticals$61.34+0.4%$46.18$23.95▼$64.71$9.78B0.281.93 million shs512,662 shsTGTXTG Therapeutics$31.50-0.8%$32.30$21.16▼$46.48$5.00B1.882.45 million shs635,063 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLKAllakos0.00%0.00%0.00%0.00%-45.57%BPMCBlueprint Medicines0.00%0.00%0.00%+0.96%+45.62%GLPGGalapagos-0.44%-4.98%-1.82%+14.18%+5.70%IONSIonis Pharmaceuticals-3.26%+0.16%+39.56%+69.02%+44.82%TGTXTG Therapeutics-1.27%-1.95%+13.07%-9.29%+33.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLKAllakos$0.33$0.33$0.22▼$1.56$29.74M0.151.25 million shsN/ABPMCBlueprint Medicines$129.46$128.90$73.04▼$129.65$8.36B0.891.55 million shsN/AGLPGGalapagos$32.02+0.4%$31.95$22.36▼$33.86N/A0.22313,870 shs50,090 shsIONSIonis Pharmaceuticals$61.34+0.4%$46.18$23.95▼$64.71$9.78B0.281.93 million shs512,662 shsTGTXTG Therapeutics$31.50-0.8%$32.30$21.16▼$46.48$5.00B1.882.45 million shs635,063 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLKAllakos0.00%0.00%0.00%0.00%-45.57%BPMCBlueprint Medicines0.00%0.00%0.00%+0.96%+45.62%GLPGGalapagos-0.44%-4.98%-1.82%+14.18%+5.70%IONSIonis Pharmaceuticals-3.26%+0.16%+39.56%+69.02%+44.82%TGTXTG Therapeutics-1.27%-1.95%+13.07%-9.29%+33.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLKAllakos 2.33Hold$3.00811.58% UpsideBPMCBlueprint Medicines 2.11Hold$130.000.42% UpsideGLPGGalapagos 1.17Strong Sell$26.00-18.79% DownsideIONSIonis Pharmaceuticals 2.81Moderate Buy$67.8810.66% UpsideTGTXTG Therapeutics 2.75Moderate Buy$46.2546.83% UpsideCurrent Analyst Ratings BreakdownLatest ALLK, BPMC, IONS, GLPG, and TGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025IONSIonis PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$70.00 ➝ $80.009/3/2025IONSIonis PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$69.00 ➝ $84.009/3/2025IONSIonis PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$40.00 ➝ $45.009/3/2025IONSIonis PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$58.00 ➝ $78.009/3/2025IONSIonis PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$40.00 ➝ $70.009/2/2025IONSIonis PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$83.00 ➝ $96.009/2/2025IONSIonis PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$55.00 ➝ $70.009/2/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$70.00 ➝ $95.008/25/2025IONSIonis PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$48.00 ➝ $49.008/25/2025IONSIonis PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$55.008/5/2025GLPGGalapagosDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold ➝ Sell(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLKAllakosN/AN/AN/AN/A$1.93 per shareN/ABPMCBlueprint Medicines$562.12M14.87N/AN/A$4.70 per share27.54GLPGGalapagos$298.31MN/A$0.73 per share44.10$47.57 per shareN/AIONSIonis Pharmaceuticals$705M13.87N/AN/A$3.73 per share16.44TGTXTG Therapeutics$454.07M11.01$0.12 per share268.08$1.43 per share22.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLKAllakos-$185.70M-$1.32N/AN/AN/AN/A-140.87%-86.22%N/ABPMCBlueprint Medicines-$67.09M-$2.47N/A199.17N/A-27.70%-64.60%-17.22%10/28/2025 (Estimated)GLPGGalapagos$80.16MN/A0.00N/AN/AN/AN/AN/A10/22/2025 (Estimated)IONSIonis Pharmaceuticals-$453.90M-$1.84N/AN/AN/A-28.25%-45.29%-8.99%11/5/2025 (Estimated)TGTXTG Therapeutics$23.38M$0.3785.1231.50N/A13.31%26.05%9.58%11/3/2025 (Estimated)Latest ALLK, BPMC, IONS, GLPG, and TGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025TGTXTG Therapeutics$0.32$0.17-$0.15$0.17$147.76 million$141.15 million7/30/2025Q2 2025IONSIonis Pharmaceuticals$0.19$0.70+$0.51$0.70$270.90 million$452.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLKAllakosN/AN/AN/AN/AN/ABPMCBlueprint MedicinesN/AN/AN/AN/AN/AGLPGGalapagosN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLKAllakosN/A6.086.08BPMCBlueprint Medicines1.012.802.75GLPGGalapagosN/A8.087.99IONSIonis Pharmaceuticals0.992.872.86TGTXTG Therapeutics0.893.862.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLKAllakos84.64%BPMCBlueprint MedicinesN/AGLPGGalapagos32.46%IONSIonis Pharmaceuticals93.86%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipALLKAllakos16.12%BPMCBlueprint Medicines4.21%GLPGGalapagos2.91%IONSIonis Pharmaceuticals2.71%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLKAllakos19090.38 million74.94 millionOptionableBPMCBlueprint Medicines64064.58 million61.86 millionOptionableGLPGGalapagos1,310N/AN/AOptionableIONSIonis Pharmaceuticals1,069159.39 million155.07 millionOptionableTGTXTG Therapeutics290158.67 million141.78 millionOptionableALLK, BPMC, IONS, GLPG, and TGTX HeadlinesRecent News About These CompaniesGreat Lakes Advisors LLC Takes $401,000 Position in TG Therapeutics, Inc. $TGTXSeptember 15 at 3:50 AM | marketbeat.comIntech Investment Management LLC Grows Stock Holdings in TG Therapeutics, Inc. $TGTXSeptember 15 at 3:19 AM | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Director Sagar Lonial Sells 20,852 SharesSeptember 14 at 5:32 PM | marketbeat.comUnited Services Automobile Association Purchases Shares of 8,531 TG Therapeutics, Inc. $TGTXSeptember 14 at 4:02 AM | marketbeat.comInsider Selling: TG Therapeutics (NASDAQ:TGTX) Director Sells 20,852 Shares of StockSeptember 13 at 6:38 AM | insidertrades.comWoodline Partners LP Takes $21.02 Million Position in TG Therapeutics, Inc. $TGTXSeptember 13 at 4:36 AM | marketbeat.comTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual MeetingSeptember 10, 2025 | globenewswire.comTG Therapeutics Begins Enrollment in Phase 3 Trial for Subcutaneous BRIUMVI in Patients with Relapsing Multiple SclerosisSeptember 8, 2025 | quiverquant.comQTG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced EnrollmentSeptember 8, 2025 | globenewswire.comCinctive Capital Management LP Purchases Shares of 14,145 TG Therapeutics, Inc. $TGTXSeptember 8, 2025 | marketbeat.comWhy TG Therapeutics (TGTX) Is Up 9.8% After Launching Another $100 Million Buyback ProgramSeptember 7, 2025 | finance.yahoo.comBanque Transatlantique SA Invests $610,000 in TG Therapeutics, Inc. $TGTXSeptember 6, 2025 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Shares Gap Up - Still a Buy?September 5, 2025 | marketbeat.comTG Therapeutics, Inc. (TGTX) Presents at Cantor Global Healthcare Conference 2025 TranscriptSeptember 4, 2025 | seekingalpha.com683 Capital Management LLC Reduces Holdings in TG Therapeutics, Inc. $TGTXSeptember 4, 2025 | marketbeat.comTG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | globenewswire.comWhy Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report?September 3, 2025 | zacks.comTG Therapeutics completes share repurchase program, authorize new $100M programSeptember 3, 2025 | msn.comTG Therapeutics Board Authorizes New $100M Share Repurchase ProgramSeptember 3, 2025 | msn.comTG Therapeutics Completes $100 Million Share Repurchase Program and Authorizes New $100 Million Repurchase InitiativeSeptember 3, 2025 | quiverquant.comQTG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million ProgramSeptember 3, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMedtronic: The Opportunity Gets Healthier for Income InvestorsBy Thomas Hughes | August 19, 2025Archer's Flight Milestones & Defense Wins Excite Wall Street By Jeffrey Neal Johnson | August 20, 2025Nextracker Stock Rockets as AI and Solar Tailwinds AlignBy Thomas Hughes | August 21, 2025Toll Brothers: A Great Buy and Hold Stock With Risks in 2025By Thomas Hughes | August 21, 2025Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift4By Leo Miller | August 18, 2025ALLK, BPMC, IONS, GLPG, and TGTX Company DescriptionsAllakos NASDAQ:ALLKAllakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.Blueprint Medicines NASDAQ:BPMCBlueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Galapagos NASDAQ:GLPG$32.02 +0.14 (+0.42%) As of 12:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Ionis Pharmaceuticals NASDAQ:IONS$61.34 +0.24 (+0.38%) As of 12:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.TG Therapeutics NASDAQ:TGTX$31.50 -0.25 (-0.79%) As of 12:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Why Opendoor Stock Is Soaring—and May Just Be Starting Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
